MTTP Genotype

Two people can eat the same diet, drink the same amount, and end up with very different amounts of fat stored in their liver. A piece of that difference is written into a gene called MTTP (microsomal triglyceride transfer protein). This test reads which version of that gene you inherited.

The version you carry can nudge your liver toward storing extra fat, shift your cholesterol and triglyceride numbers in unexpected directions, and in rare cases explain why a routine lipid panel looks strange. It is a one-time read on a piece of biology that standard blood work cannot see directly.

What MTTP Actually Does

The MTTP gene builds a protein that lives inside the cells of your liver and small intestine. Its job is to load fat onto a larger carrier protein called ApoB (apolipoprotein B), creating the fat-carrying particles that travel through your blood. Without this loading step, fat gets stuck inside cells instead of being shipped out.

That makes MTTP a quiet gatekeeper for two things at once: how much fat stays in your liver, and how much fat-and-cholesterol cargo enters your bloodstream. Genetic variants in this gene tip that balance in different directions depending on which version you carry.

Fatty Liver Risk

Several common variants in MTTP have been tied to non-alcoholic fatty liver disease (NAFLD), a condition where extra fat builds up in liver cells without heavy alcohol use. In a study of about 1,160 Han Chinese adults, the C version at a spot called rs1800804 was tied to a higher chance of fatty liver, while two other variants (rs1057613 and rs3805335) appeared protective.

In obese Han Chinese children, a coding variant called rs2306986 stood out as an independent risk factor for fatty liver and was tied to higher ALT (alanine aminotransferase, a liver enzyme that rises when liver cells are stressed), higher LDL cholesterol, higher ApoB, and more fat in the liver itself.

The most studied variant is in the gene's promoter, the on-off switch region, and is written as the -493G/T variant (rs1800591). In adults with type 2 diabetes, carrying the G version was linked to higher ALT and signs pointing toward steatohepatitis, the inflamed form of fatty liver. In biopsy-confirmed cases of NASH (non-alcoholic steatohepatitis), the G version and GG combination showed up more often, with more fat in liver tissue and more advanced disease stage.

In people with hepatitis C, the picture sharpens further. Across pooled studies, carriers of the T version (GT or TT) with hepatitis C genotype 3 infection had roughly 12 times the risk of liver steatosis compared with non-carriers, with individual studies reporting estimates ranging from about 8 to 16 times the risk. A meta-analysis combining multiple studies confirmed that the T version increases steatosis risk specifically in hepatitis C genotype 3.

Effects on Cholesterol and Triglycerides

What MTTP variants do to your cholesterol depends heavily on who you are and which variant you carry. The same -493G/T variant can push numbers in opposite directions in different groups.

Source: Ledmyr et al. 2002; Lundahl et al. 2000; Okumura et al. 2009; Couture et al. 2000.

What this means for you: a single MTTP variant does not predict your cholesterol numbers by itself. Population, diet, and other genes shift the effect. The most useful read on this test is when it is interpreted alongside a real lipid panel and a clinical picture, not in isolation.

Reconciling the Mixed Findings

It can feel contradictory that one variant raises liver fat in one study and lowers cholesterol in another. The resolution is that MTTP sits at a fork in the road. When MTTP is less active, your liver exports less fat into the blood, which can lower circulating cholesterol, but the fat that does not leave can accumulate inside liver cells. Both findings reflect the same underlying biology pulling in two directions at once.

Rare and Severe Variants

Two copies of a damaging MTTP variant cause a rare condition called abetalipoproteinemia, where the body cannot make ApoB-containing fat carriers at all. This shows up early in life with very low cholesterol, fat malabsorption, vitamin deficiencies, and neurological problems. More than 60 distinct pathogenic MTTP variants have been described to date, and clinical reports suggest that people diagnosed later in childhood tend to accumulate more complications than those identified early, which is why earlier genetic identification is thought to protect against long-term damage.

A milder coding variant called I128T (rs3816873), studied in a UK Biobank analysis of 489,404 people, was linked to less liver fat and lower LDL cholesterol and ApoB at the same time, without a clean loss-of-function pattern. This is the kind of variant where carrying it may actually shift biology in a useful direction.

Drug Response

MTTP is also the direct target of a medication called lomitapide, used for homozygous familial hypercholesterolemia, an inherited condition causing extremely high cholesterol. In a small cohort of 13 people on this drug, several MTTP variants (rs17533489, rs79194015, rs745075) were more common among those whose LDL cholesterol dropped by more than 50%. In hepatitis C genotype 4 infection, the GT version of the -493 variant independently predicted a better response to interferon-based antiviral therapy. These are early findings in narrow populations, but they suggest your MTTP genotype may eventually help match certain treatments to the people most likely to benefit.

Why This Test Is One Time

Your MTTP genotype was set the day you were conceived and will not change. There is no reason to repeat this test once you have a clean, confirmed result. The ongoing value comes from companion testing that tracks the downstream consequences of your genotype: lipid panels, liver enzymes, and imaging when appropriate. If you carry a high-risk MTTP pattern, those downstream tests deserve closer and more frequent attention than they would for someone without the variant.

A practical cadence: confirm your MTTP result once, then anchor it to at least annual lipid panels and liver enzyme checks. If you are also working on liver fat through diet, weight, or alcohol changes, retest the downstream markers every three to six months while making changes, then settle into annual tracking.

What an Unexpected Result Should Prompt

If you carry a high-risk MTTP variant tied to fatty liver and you also have rising ALT, an elevated waist measurement, or insulin resistance, that combination is a stronger signal than any one finding alone. The natural next steps include a full liver enzyme panel, a fasting insulin and glucose check, a comprehensive lipid panel with ApoB, and consideration of liver imaging such as a FibroScan or MRI-based fat measurement.

If you carry an MTTP variant tied to unusually low LDL cholesterol or ApoB, especially with a family history of fat malabsorption, vitamin deficiency, or neurological symptoms, a referral to a lipidologist or genetic counselor makes sense. Rare biallelic MTTP variants are uncommon but actionable, and confirmatory sequencing through a clinical lab may be appropriate before any clinical conclusions are drawn.

When Results Can Be Misleading

Genetic tests come with their own confounders, different from those of blood biomarkers.

• Variant panel coverage: this test detects the specific MTTP variants the assay is designed to find. A normal result does not rule out a rarer MTTP variant that the panel does not look for.
• Ethnic-specific variant frequency: many of the strongest MTTP-disease links come from studies in Han Chinese, Japanese, or European cohorts, and the clinical meaning of a given variant can differ across ancestries.
• Variant of uncertain significance: occasionally a panel will report an MTTP change whose effect on protein function is not yet known. These are not actionable on their own and may need functional or family-based analysis.
• Direct-to-consumer versus clinical-grade testing: a result from a clinical-grade lab is held to a different standard than a result you might have seen on a recreational genomics report. If your only prior MTTP information came from a non-clinical source, a clinical-grade confirmation is worth doing before acting on it.

Carrying a risk variant is not the same as developing the disease. Genetics is one input among many. Diet, weight, alcohol use, viral hepatitis status, and other genes all interact with MTTP variants to determine what actually happens in your body over a lifetime.